'Partner of Choice' aims to quantify medical affairs initiatives
Clinical SCORE’s VP of Medical Affairs Research, Gary Kaplan, told us Partner of Choice addresses the industry’s need for a non-monetary way to assess medical affair team’s performance, while maintaining regulatory compliance.
"We've watched medical affairs groups play an increasingly important role in recent years. At the same time, tighter budgets put them under tremendous performance pressure," he said.
In fact, recent reports state the medical affairs team is one of the most involved in Phase IV study development. Of the Ph IV teams surveyed as part of the report from Cutting Edge Information, 75% reported that medical affairs functions remain “a constant presence during post-marketing execution.”
According to the company, the solution uses non-monetary metrics and key performance indicators (KPIs) to quantify the value of medical affairs initiatives. Results are presented through Clinical SCORE's proprietary “KPI Konsole.”
"Today's consultative model is highly nuanced, measures like ‘call numbers’ aren't adequate," explained Kaplan. "This new paradigm calls for a fresh approach to metrics," he said, adding that the initial response has been "overwhelmingly positive."
In addition to Partner of Choice, Clinical SCORE's research offerings also include ATTUNE Analytics to enhance clinical operations and CRO/sponsor relationships, Clinical Trial Insights (CTI) and CTI PLUS to optimize post-clinical and commercial marketing efforts.
